Lewis M Slater

Title(s)Professor Emeritus, Medicine
SchoolSchool of Medicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
Phone(714) 456-5153
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Bortezomib decreases the magnitude of a primary humoral immune response to transfused red blood cells in a murine model. Transfusion. 2017 01; 57(1):82-92. Natarajan P, Liu J, Santhanakrishnan M, Gibb DR, Slater LM, Hendrickson JE. PMID: 27734515; PMCID: PMC5559200.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    2. Excessive therapeutic response in a case of blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol. 2012 Jan; 10(1):56-9. Shieh MP, Reisian N, Walavalkar V, Slater LM, Lambrecht N. PMID: 22398810.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    3. Enhancement of leukemia rejection by mice successfully treated for L1210 leukemia due to low dose compared to high dose VP-16. Leuk Res. 2002 Feb; 26(2):203-6. Slater LM, Stupecky M, Sweet P, Osann KE. PMID: 11755470.
      View in: PubMed   Mentions: 5     Fields:    Translation:Animals
    4. Etoposide induction of tumor immunity in Lewis lung cancer. Cancer Chemother Pharmacol. 2001 Oct; 48(4):327-32. Slater LM, Stupecky M, Sweet P, Osann K, Eklof A, Arquilla ER. PMID: 11710634.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    5. Phase I/II trial of low dose cyclosporin A with EP for advanced non-small cell lung cancer. Lung Cancer. 1997 Oct; 18(2):189-98. Ross HJ, Cho J, Osann K, Wong SF, Ramsinghani N, Williams J, Downey-Hurtado N, Slater LM. PMID: 9316010.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    6. Superiority of cyclosporin A over PSC-833 in enhancement of VP-16 efficacy in murine tumors in vivo. Cancer Chemother Pharmacol. 1997; 39(5):452-4. Slater LM, Sweet P, Stupecky M, Osann K. PMID: 9054960.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    7. Cyclosporin A enhances paclitaxel toxicity against leukemia and respiratory epithelial cancers. Clin Cancer Res. 1997 Jan; 3(1):57-62. Ross HJ, Canada AL, Slater LM. PMID: 9815538.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    8. Cyclosporin A/VP-16 produced immunity to L1210 leukemia: the participation of cytotoxic CD8 T-lymphocytes. Clin Immunol Immunopathol. 1995 Jun; 75(3):239-45. Slater LM, Sweet P, Stupecky M, Reynolds JT. PMID: 7768041.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    9. Radioimmunodetection of Hodgkin's disease and non-Hodgkin's lymphomas with monoclonal antibody to eosinophil peroxidase. J Nucl Med. 1993 Aug; 34(8):1246-53. Samoszuk MK, Anderson AL, Ramzi E, Wang F, Braunstein P, Lutsky J, Majmundar H, Slater LM. PMID: 8326380.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    10. Novel nucleolar and nuclear morphology in a vincristine-dependent human leukemia cell line (L100). Exp Cell Res. 1992 Jan; 198(1):170-4. Slater LM, Sweet P, Hsu TC, Chan PK. PMID: 1727053.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    11. Cyclosporin A potentiation of VP-16: production of long-term survival in murine acute lymphatic leukemia. Cancer Chemother Pharmacol. 1992; 31(1):53-6. Slater LM, Cho J, Wetzel M. PMID: 1458558.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    12. Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro. Cancer Chemother Pharmacol. 1992; 30(2):152-4. Osann K, Sweet P, Slater LM. PMID: 1600596.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    13. Development of cyclosporin A mediated immunity in L1210 leukaemia. Br J Cancer. 1991 Dec; 64(6):1098-102. Slater LM, Wetzel M, Cho J, Sweet P. PMID: 1764373; PMCID: PMC1977840.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    14. Cyclosporin A and verapamil enhancement of daunorubicin-produced nucleolar protein B23 translocation in daunorubicin-resistant and -sensitive human and murine tumor cells. Cancer Res. 1989 Feb 01; 49(3):677-80. Sweet P, Chan PK, Slater LM. PMID: 2910487.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    15. Albumin inhibition of the antileukemic activity of hydroxylated phenothiazines. Anticancer Drug Des. 1987 Apr; 1(4):297-301. Slater LM, Sweet PM, Stupecky MM, Murray SL, Wetzel MW. PMID: 3450301.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    Lewis's Networks
    Concepts (93)
    Derived automatically from this person's publications.
    Co-Authors (1)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department